Article info
Original article
Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience
- Correspondence to Jan Miroslav Hartinger, Farmakologický ústav, Univerzita Karlova v Praze 1 lekarska fakulta, Prague 12800, Czech Republic; hartinger.jan{at}vfn.cz
Citation
Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience
Publication history
- Received November 17, 2017
- Revised January 11, 2018
- Accepted February 6, 2018
- First published February 28, 2018.
Online issue publication
May 01, 2020
Article Versions
- Previous version (28 June 2019).
- Previous version (28 June 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists (unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.